GLP-3
Also known as Retatrutide · LY3437943
Triple GIP / GLP-1 / glucagon agonist — A 39-amino-acid triple agonist targeting GIP, GLP-1 and glucagon receptors, studied for metabolic regulation and body composition in research models.
Latest released COA: 99.09%Lyophilized powder
Available vial sizes
- 10 mg$67.99In stock
- 20 mg$117.99In stock
From $67.99In stock
View purchase options
Specifications
| CAS number | 2381089-83-2 |
|---|
| Molecular weight | 4731.4 g/mol |
|---|
| Form | Lyophilized powder |
|---|
Research use only. Not for human or veterinary use, consumption, diagnosis, treatment, or therapeutic purposes.
Documentation
Certificates of Analysis
Batch-specific, third-party lab certificates. Each COA is published here once its lot has been tested — preview the results, then open the full PDF.
Research context
GLP-3 research, identity and references
Also known as Retatrutide, LY3437943
What is retatrutide in the published literature?
Retatrutide is described in the literature as an investigational peptide agonist of the GIP, GLP-1, and glucagon receptors. The references below establish research identity and study context; they do not establish the quality, safety, or intended use of any material sold by Astral.
CAS number2381089-83-2
Molecular weight4731.4 g/mol
Sequence39-amino-acid triple agonist (GIP / GLP-1 / glucagon)
Human phase 2 trial
Human phase 2 trial
Jastreboff AM, Kaplan LM, Frías JP, et al. New England Journal of Medicine (2023).
Defines the investigational triple-receptor agonist and its clinical research context; it is not evidence about Astral material.
PMID 37366315 · DOI 10.1056/NEJMoa2301972
Human phase 2a trial
Human phase 2a trial
Sanyal AJ, Kaplan LM, Frias JP, et al. Nature Medicine (2024).
Reports a separate clinical research setting for the same investigational molecule; no product-quality inference is made.
PMID 38858523 · DOI 10.1038/s41591-024-03018-2
Investigational-drug review
Investigational-drug review
Kaur M, Misra S European Journal of Clinical Pharmacology (2024).
Summarizes the investigational profile reported in the trial literature. Describes a drug under study, not material sold by Astral.
PMID 38367045 · DOI 10.1007/s00228-024-03646-0
Scientific review
Scientific review
Tetelbaun L, Mullally JA, Frishman WH Cardiology in Review (2024).
Places the triple-agonist mechanism in its research context. No inference about product identity or quality follows from it.
PMID 39724554 · DOI 10.1097/CRD.0000000000000793
Editorially curated and source-verified; not independently peer-reviewed by Astral. Last source check: 2026-08-04. How sources are selected.
Check released lot evidence →